Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
S Dallavalle, V Dobričić, L Lazzarato, E Gazzano… - Drug Resistance …, 2020 - Elsevier
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
S Dallavalle, V Dobričić, L Lazzarato… - Drug resistance …, 2020 - pubmed.ncbi.nlm.nih.gov
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
[PDF][PDF] IMPROVEMENT OF CONVENTIONAL ANTI-CANCER DRUGS AS NEW TOOLS AGAINST MULTIDRUG RESISTANT TUMORS
S Dallavallea, V Dobričićb, L Lazzaratoc, E Gazzanod… - core.ac.uk
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
S Dallavalle, V Dobricic, L Lazzarato… - DRUG RESISTANCE …, 2020 - air.unimi.it
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
S Dallavalle, V Dobričić, L Lazzarato… - … and Commentaries in …, 2020 - europepmc.org
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
S Dallavalle, V Dobričić, L Lazzarato… - Drug Resistance …, 2020 - farfar.pharmacy.bg.ac.rs
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
S Dallavalle, V Dobricic, L Lazzarato… - DRUG RESISTANCE …, 2020 - iris.unito.it
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
[PDF][PDF] IMPROVEMENT OF CONVENTIONAL ANTI-CANCER DRUGS AS NEW TOOLS AGAINST MULTIDRUG RESISTANT TUMORS
S Dallavallea, V Dobričićb, L Lazzaratoc, E Gazzanod… - air.unimi.it
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …